Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ribomic, Inc. ( (JP:4591) ) just unveiled an announcement.
Ribomic reported non-consolidated operating revenue of ¥3 million for the year ended March 31, 2026, up from ¥2 million a year earlier, but continued to post losses, with operating loss widening to ¥1,207 million and net loss at ¥1,145 million. Despite a high equity ratio of 95.4% and higher year-end cash and cash equivalents of ¥1,927 million supported by financing inflows, net assets declined, no dividends were declared, and the company forecasts a further full-year loss for the year ending March 2027 even as it targets a sharp increase in revenue.
The company’s financial outlook for the year ending March 31, 2027 projects operating revenue of ¥17 million, but also anticipates a deeper operating loss of ¥1,547 million and net loss of ¥1,543 million, indicating continued heavy investment relative to its small revenue base. With no change in accounting policies, an expanded share count, and ongoing negative cash flow from operations offset by financing, stakeholders face a scenario of sustained dilution and losses as Ribomic pursues its development strategy without near-term prospects for shareholder returns.
More about Ribomic, Inc.
Ribomic Inc., listed on the Tokyo Stock Exchange under code 4591, operates in the biotechnology and pharmaceutical sector. The company focuses on developing nucleic acid medicine technologies and related therapeutic candidates, positioning itself as a research-driven player targeting innovative treatments in specialized medical markets.
Average Trading Volume: 2,727,196
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen4.24B
For detailed information about 4591 stock, go to TipRanks’ Stock Analysis page.